Glucose Fresenius

Glucose Fresenius is an intravenous solution that contains glucose monohydrate as its sole active ingredient. It is supplied in a sterile liquid form for parenteral administration, used as an energy source or carrier solution in clinical settings. The product is manufactured for the European market and is available by prescription only. No strength is disclosed on the label, and it is classified as an excipient rather than a therapeutic drug.

Glucose Fresenius is employed in healthcare facilities primarily as a source of carbohydrate calories and as a diluent for intravenous drug preparations.

- Providing caloric support for patients unable to receive oral nutrition. - Serving as a carrier solution for the reconstitution of powdered medications administered intravenously. - Maintaining blood glucose levels during perioperative or critical‑care situations. - Assisting in the management of hypoglycemia when administered under medical supervision. - Facilitating fluid balance when combined with electrolytes in parenteral nutrition regimens. - Diluting concentrated intravenous medications to achieve the desired infusion concentration.

Adverse reactions to Glucose Fresenius are generally related to the intravenous administration of a carbohydrate solution and may vary with infusion rate and patient condition.

Common: - Mild hyperglycemia when administered in large volumes. - Local irritation or pain at the infusion site. - Nausea or vomiting if the solution is infused rapidly. - Electrolyte shifts such as mild hyponatremia when combined with other fluids. - Transient increase in serum osmolality, usually self‑limited.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions including rash, urticaria, or anaphylaxis. - Volume overload causing pulmonary edema in patients with compromised cardiac function. - Metabolic acidosis in patients receiving large volumes without appropriate monitoring.

When using Glucose Fresenius, clinicians should observe several precautionary measures to ensure patient safety and optimal therapeutic outcomes.

- Verify patient’s baseline blood glucose and adjust infusion rate accordingly. - Assess fluid balance and cardiac status to avoid volume overload. - Use aseptic technique to prevent contamination of the intravenous solution. - Monitor electrolytes, especially sodium and potassium, during prolonged infusions. - Avoid rapid infusion rates that may cause hyperglycemia or osmotic shifts. - Consider renal function, as impaired clearance can affect glucose handling. - Document any adverse reactions promptly in the patient’s medical record.

Glucose Fresenius may interact with other intravenous therapies or medications; awareness of potential interactions helps prevent complications.

Avoid: - Co‑administration with high‑dose insulin infusions without proper monitoring, as it can precipitate severe hypoglycemia. - Mixing with calcium‑containing solutions in the same line, which may cause precipitation.

Use with caution: - Concurrent use of diuretics that affect fluid balance; monitor for signs of volume overload. - Administration alongside hypertonic saline or other hyperosmolar solutions; adjust infusion rates to avoid rapid shifts in serum osmolality. - Use with beta‑adrenergic agonists that may increase glycogenolysis, potentially raising blood glucose levels. - Patients receiving total parenteral nutrition; coordinate glucose delivery to match caloric needs.